{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-097992","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.405303+00:00","generated_at":"2026-05-17T04:18:23.844850+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Esperion prices $75M public offering of 30M shares at $2.50 each","bullets":["Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).","Expected close October 9, 2025; use proceeds for NEXLETOL/NEXLIZET commercialization, R&D, working capital.","Piper Sandler & Cantor Fitzgerald are joint book-running managers; co-managers include Citizens JMP, H.C. Wainwright, Needham.","Shares sold under existing shelf registration statement (File No. 333-286631) effective April 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-097992","json":"https://secwatch.observer/filing/0001104659-25-097992.json","markdown":"https://secwatch.observer/filing/0001104659-25-097992.md","text":"https://secwatch.observer/filing/0001104659-25-097992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/0001104659-25-097992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/tm2527818d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:18:23.844850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}